# BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study

> **NCT02936492** · PHASE1 · TERMINATED · sponsor: **Bayer** · enrollment: 32 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** BAY1003803 0.01% lipophilic cream
- **DRUG:** BAY1003803 0.1% lipophilic cream
- **DRUG:** BAY1003803 0.01% ointment
- **DRUG:** BAY1003803 0.1% ointment
- **DRUG:** Lipophilic cream vehicle
- **DRUG:** Ointment vehicle
- **DRUG:** Clobetasol propionate

## Key facts

- **NCT ID:** NCT02936492
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-24
- **Primary completion:** 2017-04-18
- **Final completion:** 2017-10-16
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02936492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02936492, "BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02936492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*